Healthcare
Theralase Technologies Inc.(TLTFF)
Live Price
Offline$0.16
-5.88% today
1Y Change
+21.43%
Window
Jun 20, 2025 β Jun 15, 2026
- Market Cap
- $80.00M
- Revenue Growth
- -3.4%
- EPS Growth
- +14.9%
- Dividend Yield
- 0.0%
Coverage: 248 bars Β· Jun 20, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theralase Technologies Inc. (TLTFF) is a Healthcare stock with a market cap of $80.00M and listed on OTC. The stock last traded around $0.16 and up 21.4% across the available one-year price window (Jun 20, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of -3.4%, EPS growth of +14.9%, a dividend yield of 0.0%. What stands out right now is revenue -3.4%, EPS +14.9%, free cash flow +18.6% with operating margin -440.4% and ROIC -312.1%. Valuation already assumes a fairly strong business story at price/sales 78.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TLTFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.4% vs +7.6% peer median
Operating Margin
Below sector median
-440.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 28, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -3.4% and EPS is at +14.9%, with operating margin around -440.4%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 26, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 28, 2026 | β | +6.3% | +6.3% | β |
2026 Apr 30, 2026 | +49.8% | -1.3% | -30.7% | -26.4% |
2025 Nov 10, 2025 | -34.4% | +1.9% | -6.2% | -24.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLTFF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
TLTFF Max Drawdown
-44.44%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TLTFF and SPY.
Company Overview
Theralase Technologies Inc.
Other OTC
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette GuΓ©rin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.
- Leadership
- Roger John Dumoulin-White
- IPO Date
- Apr 5, 2010
- Employees
- 14
- Street Address
- 41 Hollinger Road
- Mailing
- Toronto, ON, M4B 3G4
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 416 699 5273
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 78.3
- Price/Book
- 70.0
Growth
- Revenue
- -3.4%
- EPS
- +14.9%
- Free Cash Flow
- +18.6%
Profitability
- Gross Margin
- 49.3%
- Operating Margin
- -440.4%
- Net Margin
- -434.9%
- ROE
- -315.1%
- ROIC
- -312.1%
Balance Sheet
- Debt/Equity
- 0.29
- Current Ratio
- 0.83
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.